XML 50 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations (Details Textual) (USD $)
 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Jan. 31, 2011
CyDex
medication
licensee
product
Dec. 31, 2013
CyDex
employee_equivalent
Dec. 31, 2012
CyDex
Jan. 31, 2011
CyDex
Complete technology
Jan. 31, 2011
CyDex
Trademark and trade name
Dec. 31, 2013
CyDex
Customer relationships
Jan. 31, 2011
CyDex
Customer relationships
Business Acquisition [Line Items]                    
Number of FDA-approved medications       6            
Number of licensees       4            
Cash paid to CyDex shareholders       $ 31,572,000            
Percentage of related revenue         20.00%          
Amount exceeds to get related revenue for CyDex share holders         15,000,000          
Percentage of related revenue additional         10.00%          
Aggregate CyDex-related revenue         35,000,000          
Discount rate used to estimate future cash flows       21.50%     20.50% 20.50%   21.50%
Gain (loss) on asset disposal 5,000 (17,000) (456,000)   500,000 0        
Number of employees required         5          
Investments for acquiring employees         1,500,000          
Business combination, weighted-average amortizaiton period intangible assets         20 years       20 years  
In-process research and development       $ 3,200,000            
Number of acquirees in-process research and development products       2